Abstract

Off-target binding, batch variability, and multiple productive chains are not just a once in a research blue moon happenstance. They are the direct, common results of industry-wide insufficient antibody characterization that has, is, or will, wreak havoc on your research. Based on their world-leading expertise in proteomics and antibody analysis, Rapid Novor discusses the negative impacts of insufficient Ab characterization and presents a solution that can help researchers confidently proceed with their research.

Related Posts

Enriching Engineered T Cells with Antibody Sequencing & Modulation

May 10th, 2022

Breakthrough Bispecific Antibody R&D Techniques

March 29th, 2022

Species Agnostic Antibody Sequencing & Discovery in Veterinary Medicine R&D

February 20th, 2022

Leveraging the Power of Next Generation Protein Sequencing to Shape Tomorrow’s In Vitro Diagnostics

February 3rd, 2022

Why Is Sequence Blindness Acceptable with Antibodies?

January 30th, 2022

Recombinant Therapeutic pAbs are Now Possible

January 20th, 2022

Newsletter for All Things Protein Sequencing

Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.

Talk to Our Scientists.

We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 5000 antibodies and we are eager to help you.